Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02830451 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metastatic Tumor Research and Outcomes Network

Study acronym: MTRON
StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 15 entries Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 2417 participants (planned 960)
    • Primary and study completion dates changed from estimate of Aug 15, 2026 to Aug 18, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 25 words
    • Site details revised at 1 of 24 sites
  2. Primary and study completion dates: Dec 2025 to Aug 15, 2026
    • Study sites: 25 to 24
    v16
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 25 of 25 sites
    v15
  4. Re-verified, no change to tracked fieldsv14
  5. Primary and study completion dates: Dec 2023 to Dec 2025v13
Show 11 earlier versionsHide 11 earlier versions
  1. Re-verified, no change to tracked fieldsv12
  2. Site details revised at 4 of 25 sitesv11
  3. Lead sponsor: AO Clinical Investigation and Publishing Documentation to AO Innovation Translation Centerv10
  4. Primary and study completion dates: Dec 2019 to Dec 2023v9
  5. Enrollment target: 780 to 960
    • Site details revised at 5 of 25 sites
    v8
  6. Site details revised at 1 of 25 sitesv7
  7. Site details revised at 8 of 25 sitesv6
  8. Site details revised at 6 of 25 sitesv5
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2017 to Nov 15, 2017
    • Site details revised at 25 of 25 sites
    v4
  10. Study sites: 26 to 25v3
  11. Enrollment target: 300 to 780v2 Show 9 more changesShow less
    • Start date: Jul 2016 to Nov 2017
    • Primary endpoints: 7 to 15
    • Study sites: 1 to 26
    • Primary completion date: Sep 2019 to Dec 2019
    • Study completion date: Dec 2019
    • Eligibility criteria shortened, about 9 words
    • Secondary endpoints: 24 to 4
    • Study description expanded, about 14 words
    • Study title revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).
Trial Details
NCT Number NCT02830451
Lead Sponsor AO Innovation Translation Center
Collaborators: AO Foundation, AO Spine
Conditions
(from sponsor)		 Metastatic Spine Tumor
Related terms Neoplasm Metastasis, Neoplasms
Enrollment 2,417 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov